Business Context and Reporting Period
Niagen Bioscience, Inc. filed a Form 8-K on July 25, 2025, reporting a material definitive agreement entered into by its wholly owned subsidiary, ChromaDex, Inc. The filing covers the execution of a Sales Agreement with W. R. Grace & Co.-Conn ("Grace") effective April 1, 2025.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a new supply contract.
Material Changes and Agreement Terms
- Exclusive Supply: Grace will exclusively supply Nicotinamide-beta-Riboside Chloride ("NRCL") to the Company. Grace is prohibited from selling NRCL to third parties and must notify the Company of any new inquiries.
- Term and Renewal: The initial term runs through April 30, 2029, with automatic renewals for successive 12-month terms unless terminated with 90 days' notice.
- Purchase Obligations: The Company must purchase a minimum quantity of NRCL annually and provide monthly rolling 24-month forecasts, with the first 12 months binding upon acceptance.
- Future Licensing: The parties agreed to make a good faith effort to negotiate a supplemental License Agreement. This would grant the Company a worldwide, royalty-bearing, exclusive license to Grace's NRCL manufacturing patents, effective upon the proper termination of the Supply Agreement. No guarantee exists that this agreement will be finalized.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future performance. A key contingency noted is the uncertainty regarding the future License Agreement; there is no guarantee that the parties will successfully execute the supplemental agreement, nor are the timing or terms of such an agreement assured.
Investor Verification Checklist
- Verify the specific minimum quantity purchase obligations for NRCL, as the exact figures are omitted from this summary.
- Review the full text of the Sales Agreement (Exhibit 10.1) for confidential terms and specific quality specifications.
- Monitor future filings for the execution and terms of the potential License Agreement regarding NRCL manufacturing patents.
- Confirm the impact of the exclusive supply arrangement on the Company's cost structure and supply chain resilience.